Livestyle Intervention Clinical Trial, Ovarian Cancer

by Laurel Pracht

This year alone approximately 22,430 women will hear the words that they have ovarian cancer. The statistics are that one in 70 U.S. women will be diagnosed with ovarian cancer in her lifetime. Finding new ways to reduce recurrent disease in ovarian cancer survivors is an important focus of current ovarian cancer research.

Research suggests that maintaining a healthy lifestyle could reduce recurrent ovarian cancer risk. Fortunately the Gynecologic Oncology Group (GOG), now a legacy member of the NRG Oncology cooperative oncology group has successfully accrued 1200 women for a clinical trial, LIvES GOG-225, to examine whether lifestyle intervention improves quality of life and survival in comparison to the usual care group. The trial closed to accrual in August, 2018 with each participant’s lifestyle followed for two years. It is hoped during year 2020 preliminary data will be published.

Funding such a large study study that does not involve pharmaceuticals was secured and the West Valley Ovarian Cancer Alliance has been a yearly source of funds as generated through the Teal Ribbon charity Golf Tournament. The Alliance has donated over $100,000 in support of the LIvES trial which was possible through the generosity of the support of Phoenix West Valley businesses, individuals and the Sun City and surrounding areas golfing communities.

The LIvES clinical trial is conducted nationwide and based at the University of Arizona Cancer Center, Tucson, AZ. Together we can make a difference for our sisters, daughters and granddaughters.